In the two years since Aptinyx was spun-out from predecessor Naurex, the US biotech has gone from being a preclinical company to one with two Phase II programs and a third to enter that stage in 3Q 2018. Company president and CEO, Norbert Riedel met up with Scrip at the 2018 Biotech Showcase and revealed how Aptinyx intends to spend the $70m it raised in a series B financing late last year.
Aptinyx president and CEO Norbert Riedel speaks to Scrip
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
